期刊文献+

Src羧基端激酶抑制剂PP2对大鼠C6胶质瘤细胞生物学行为的影响及机制研究

Effects of C-terminal Src kinase inhibitor PP2 on the biological behavior of rat C6 glioma cells and related mechanisms
下载PDF
导出
摘要 目的:探讨Src羧基端激酶(C-terminal Src kinase,Src激酶)抑制剂PP2对大鼠C6胶质瘤细胞生物学行为的影响及其机制。方法用浓度为0(溶剂对照组)、2.5、5、7.5 mol/L PP2作用于C6胶质瘤细胞12 h后,分别采用CCK8、划痕实验、transwell基质胶侵袭实验观察PP2对C6胶质瘤细胞形态、增殖、侵袭和迁移的影响。免疫印迹法检测细胞核内β-catenin蛋白表达。结果不同浓度的PP2作用于C6胶质瘤细胞12 h后均能诱导细胞聚集并产生明显的形态改变,且浓度越高,聚集效果越明显。 PP2作用于C6胶质瘤细胞12 h后可明显抑制其增殖、迁移和侵袭,且呈浓度相关性,同时,细胞核内p-β-catenin蛋白表达明显减少。结论 Src激酶抑制剂PP2可能通过减少细胞核内p-β-catenin蛋白表达,从而有效抑制C6胶质瘤细胞的增殖、侵袭和迁移。 Objective To investigate the effects of C -terminal Src kinase inhibitor PP 2 on the biological behavior of rat C6 glioma cells and related mechanism .Methods C6 glioma cells were treated with 0, 2.5, 5, 7.5 mmol/L of PP2 for 12 h.Then, the effects of PPS on the morphological changes , proliferation, invasion and migration of C6 glioma cells were detected by CCK8 assay, wound healing assay and Transwell invasion assay .Furthermore, the level of β-catenin was determined by Western blotting .Results After exposure to various concentrations of PP 2 for 12 h, C6 glio-ma cells showed cell aggregation and remarkably morphological changes , which were more obvious as the concentration of PP2 increased.PP2 also significantly inhibited the proliferation , migration and invasion of C6 glioma cells in a concentra-tion-dependent manner .Meanwhile, the level of β-catenin in the nucleus was significantly decreased .Conclusion PP2 can inhibit the proliferation , migration and invasion of C 6 glioma cells through down -regulation of β-catenin ex-pression in the nucleus .
出处 《徐州医学院学报》 CAS 2016年第7期421-424,共4页 Acta Academiae Medicinae Xuzhou
基金 国家自然科学基金(81372698) 江苏省肿瘤生物治疗重点实验室课题(ZL1207) 徐州医科大学研究生科技创新计划(xyyc14-11)
关键词 C6胶质瘤细胞 Src激酶抑制剂 细胞增殖 细胞侵袭 细胞迁移 C6 glioma cells Src kinase inhibitor proliferation invasion migration
  • 相关文献

参考文献11

  • 1Coniglio S J, Segall JE. Review : molecular meehanism ol mh:roglia stimulated glioblastoma invasion [ J ]. Matrix Biol, 2013,32 ( 7 8) ,372 -380.
  • 2Wannuth M, Damoiseaux R, l,iu Y ,et al. SRC tamily kinascs: potential targets for Ihe treatment of human cancer and leukemia [ J ]. Curr Pharm Des, 2003,9 (25) :2043 - 2059.
  • 3Irby RB, Yeatman TJ. Role of Sr~' expression and activation in hu man cancer [ J ]. Oncogene, 2000,19 (49) :5636 - 5642.
  • 4李萍,傅深,章青,俞立萍,徐文才,孙宜.酪氨酸激酶抑制剂tyrphostin AG1478对乳腺癌细胞作用的机制探讨[J].肿瘤,2010,30(6):481-485. 被引量:3
  • 5Bolen JB, Rosen N, Israel MA. Increased pp60c - src tyrosyl ki- nase activity in human neuroblastoma.s is assoclalcd with anlino - terminal tyrosine phosphorylation of the src ger, c product [J]. Proc Natl Acad Sci U S A,1985, 82(21 ) :7275 -7279.
  • 6Matsunaga T, Shirasawa H, Tanabe M,et al. Expression of alter- natively spliced src messenger RNAs related to neuronal differenti- ation in human neuroblastomas [ J ]. Cancer Rcs, 1993,53 (13) : 3179 -3185.
  • 7Beierle EA, Ma X, Trujillo A, el al. Inhibition of focal adhcton kinase and src increases detachment and apoptosis in human nen- roblastoma cell lines [ J]. Mol CareivH,g, 2010.49 ( 3 ) : 224 234.
  • 8Wu L, Bernard- Trifilo JA, l,im Y, et al. Distim:t FAK -Sre- ac tivation events promote α5β1 and α4β1 integrin- stimulated nen- roblastoma cell motility [ J ]. Oneogene, 2008,27 ( 10 ) :1439 - 1448.
  • 9Tsukita S, Oishi K, Akiyama T, et al. Specitic pint tyrosine kinases of src fatally are enriched in cell - to ens junctions where the Icvel of tyrosine phosphorylali [J]. J Cell Biol, 1991,113(4) :867 -879.
  • 10Beierle EA, Ma X, Trujillo A, et al. Inhibition of focal adhesiox kinase and src increases detachment and apoptosis in human neu -roblastoma cell lines [ J]. Mol Carcinog, 2010,49 ( 3 ) : 224 - 234.

二级参考文献12

  • 1甄林林,朱旬,郑伟,王萱仪,武正炎.Tyrphostins AG1478对内分泌耐药乳腺癌细胞的作用[J].南京医科大学学报(自然科学版),2006,26(7):530-533. 被引量:1
  • 2BROWNE B C,O'BRIEN N,DUFFY M J,et al.HER-2 signaling and inhibition in breast cancer[J].Curr Cancer Drug Targets,2009,9(3):419-438.
  • 3JONE K L,BUZDAR A U.Evolving novel anti-HER2 strategies[J].Lancet Oncol,2009,10(12):1179-1187.
  • 4CHAN C T,METZ M Z,KANE S E.Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor(EGFR) kinase inhibitors[J].Breast Cancer Res Treat,2005,91(2):187-201.
  • 5MODJTAHEDI H,ESSAPEN S.Epidermal growth factor receptor inhibitors in cancer treatment:advances,challenges and opportunities[J].Anticancer Drugs,2009,20(10):851-855.
  • 6DITTMANN K,MAYER C,RODEMANN H P.Nuclear EGFR as novel therapeutic target:insights into nuclear translocation and function[J].Strahlenther Onkol,2010,186(1):1-6.
  • 7LO H W,XIA W,WEI Y,et al.Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer[J].Cancer Res,2005,65(1):338-348.
  • 8TEVAARWERK A J,KOLESAR J M.Lapatinib:a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer[J].Clin Ther,2009,31(2):2332-2348.
  • 9SHUSHAN A,ROJANSKY N,LAUFER N,et al.The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth[J].Human Reprod,2004,19(9):1957-1967.
  • 10ZHANG Y G,DU Q,FANG W G,et al.Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells[J].Int J Oncol,2008,33(3):595-602.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部